DeBogy Molecular

DeBogy Molecular is a private, preclinical-stage biotech company pioneering a permanent surface modification technology to create self-disinfecting materials. Led by a seasoned CEO and a founding team of surgeon-scientists, the company aims to address healthcare-associated infections (HAIs) and broader microbial contamination through a scalable, biocompatible coating platform. While currently pre-revenue and focused on R&D, DeBogy has demonstrated in vivo efficacy and is positioning its technology for medical, life sciences, and industrial applications.

Proprietary chemical platform for permanent surface modification that renders materials biocidal, destroying viral, bacterial, and fungal cells on contact. Applicable to a wide range of materials including metals, polymers, ceramics, and textiles.

DeBogy competes in the broad antimicrobial coatings market, which includes established players using silver, copper, and polymer-based technologies. Its key differentiator is the claim of a permanent, non-leaching, and broadly applicable chemical modification, as opposed to temporary or additive-based coatings.